Xing et al. found that ARID1A-deficient HCC cells and xenograft tumors were highly sensitive to copper treatment, this suggests that copper therapy is a promising therapeutic strategy for selectively targeting ARID1A-deficient HCC [135]. The gene discussed is ARID1A; the disease is hepatocellular carcinoma.